用低氧酸盐长期治疗麻醉症和异常性高睡眠症
Logan D Schneider1, Anne Marie Morse2, Michael J Strunc3
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Nature and science of sleep
|August 25, 2023
概括
低氧酸盐 (LXB) 为麻醉症和异常性高睡眠症提供了有效的治疗方法,改善了生活质量和功能. 与传统治疗方法相比,这种配方提供了显著的减少.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻醉症和异常性高睡眠症是慢性疾病,影响日常功能和生活质量.
- 现有的治疗方法,如氧酸盐 (SXB) 是有效的,但高含量.
- 低氧酸盐 (LXB) 是一种新型配方,具有类似的活性成分,但显著减少了.
研究的目的:
- 评估低氧酸盐 (LXB) 治疗麻醉症和异常性高睡眠症的疗效和安全性.
- 探索LXB的长期益处,包括剂量灵活性,改善生活质量和减少摄入量.
- 评估与这些睡眠障碍患者的较低消耗相关的潜在健康益处.
主要方法:
- 进行了3期临床试验,以评估在麻醉症和异常性高睡眠症患者中的LXB.
- 与SXB等现有治疗方法相比,对安全性进行了比较.
- 剂量策略包括每晚服用一次或两次,并进行个性化定位.
主要成果:
- 在麻醉症患者中,LXB的安全性与SXB一致.
- 在麻醉中,LXB有效地治疗了触角症和过度的白天嗜睡,以及异常性高睡眠症的症状.
- 观察到的好处包括改善生活质量,功能和体重减轻,因减少而带来潜在的心血管优势.
结论:
- 低氧酸盐 (LXB) 是对麻醉症和异常性高睡眠症的有效和有前途的长期治疗选择.
- 与SXB相比,LXB提供灵活的剂量和潜在的健康益处,特别是减少摄入量.
- 需要进一步的前性研究来证实LXB减少摄入量的长期心血管益处.
相关概念视频
01:07Narcolepsy
138
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
138
01:19Management of Insomnia
281
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
281
01:24Sleep-Wake Cycles
1.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.4K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
202
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
202
01:14CNS Depressants: Barbiturates and Benzodiazepines
316
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
316
01:20Antiepileptic Drugs: Potassium Channel Activators
211
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
211